NCT00074698 - Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2003

Study Completion Date

May 31, 2004

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

FG-3019

FG-3019 will be administered per dose and schedule specified in the arm description.

Trial Locations (4)

University of Michigan Health Sciences, Ann Arbor

Southwestern Medical School, Dallas

National Jewish Medical and Research Center, Denver

University of Washington Medical Center, Seattle